Literature DB >> 10849490

Prostate cancer in Taiwan: epidemiology and risk factors.

Y S Pu1.   

Abstract

The incidence of prostate cancer (PC) has been rapidly increasing in the past 10 years in Taiwan. It became the sixth common cancer in males in 1996 and resulted in 540 deaths in 1998. It was estimated that the incidence of PC would be up to 14 per 105 in the year 2000, 3-fold higher than that in 1990. Three factors may be responsible for the increase of PC in Taiwan: use of prostate specific antigen, population aging and high fat diet. A case-control study on the risk factors of PC in a patient population comprised mainly of veterans (63%) in Taiwan showed that PC patients tended to have engaged in more physical activity (adjusted odds ratio (OR): 2.16), have a lower body mass index (OR 2.0) and be less likely to consume vegetables cooked with pork lard (OR 0.47). About half of our patients had locally advanced or metastatic diseases upon diagnosis. This staging distribution was consistent in most major institutions in Taiwan and was fairly unchanged over time in the past two decades. The incidence of latent PC in Taiwan was not investigated until a pathological review of 49 cystoprostatectomy specimens recently revealed unsuspected PC in 32.7% and high-grade prostate intra epithelial neoplasia in 49% of the prostates removed. As the incidence of PC grows rapidly in Taiwan, this disease warrants more attention from the public and the authorities. More efforts should also be directed to the investigation on the risk factors for PC in the new millennium.

Entities:  

Mesh:

Year:  2000        PMID: 10849490     DOI: 10.1046/j.1365-2605.2000.00012.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  9 in total

1.  Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.

Authors:  Li-Juan Meng; Jun Wang; Wei-Fei Fan; Xiao-Lin Pu; Fu-Yin Liu; Min Yang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-02       Impact factor: 4.553

2.  Cancer Incidence Characteristic Evolution Based on the National Cancer Registry in Taiwan.

Authors:  Yu-Ching Huang; Yu-Hung Chen
Journal:  J Oncol       Date:  2020-07-22       Impact factor: 4.375

3.  Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells.

Authors:  Chi-Sheng Chien; Kun-Hung Shen; Jau-Shyang Huang; Shian-Chin Ko; Yuan-Wei Shih
Journal:  Mol Cell Biochem       Date:  2009-07-26       Impact factor: 3.396

Review 4.  Prostate cancer in Asian men.

Authors:  Kazuto Ito
Journal:  Nat Rev Urol       Date:  2014-03-04       Impact factor: 14.432

5.  Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.

Authors:  Yu-Wei Chou; Fen-Fen Lin; Sakthivel Muniyan; Frank C Lin; Ching-Shih Chen; Jue Wang; Chao-Cheng Huang; Ming-Fong Lin
Journal:  Cell Biosci       Date:  2015-07-17       Impact factor: 7.133

6.  Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study.

Authors:  Ke Li; Jie Si-Tu; Jianguang Qiu; Li Lu; Yunhua Mao; Hua Zeng; Mingkun Chen; Caiyong Lai; Heng-Jui Chang; Dejuan Wang
Journal:  Cancer Manag Res       Date:  2019-02-04       Impact factor: 3.989

7.  The impact of receptor of advanced glycation end-products polymorphisms on prostate cancer progression and clinicopathological characteristics.

Authors:  Ying-Erh Chou; Ming-Ju Hsieh; Shian-Shiang Wang; Chia-Yen Lin; Yen-Yu Chen; Yung-Chuan Ho; Shun-Fa Yang
Journal:  J Cell Mol Med       Date:  2021-10-27       Impact factor: 5.310

8.  Cadmium burden and the risk and phenotype of prostate cancer.

Authors:  Yi-Chun Chen; Yeong S Pu; Hsi-Chin Wu; Tony T Wu; Ming Kuen Lai; Chun Y Yang; Fung-Chang Sung
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

9.  The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics.

Authors:  Ying-Erh Chou; Po-Jen Yang; Chia-Yen Lin; Yen-Yu Chen; Whei-Ling Chiang; Pei-Xuan Lin; Zih-Yun Huang; Matthew Huang; Yung-Chuan Ho; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2020-10-03       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.